| Nivolumab versus everolimus in advanced renal-cell carcinoma RJ Motzer, B Escudier, DF McDermott, S George, HJ Hammers, S Srinivas, ... New England Journal of Medicine 373 (19), 1803-1813, 2015 | 5484 | 2015 |
| Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial RJ Motzer, B Escudier, S Oudard, TE Hutson, C Porta, S Bracarda, ... The Lancet 372 (9637), 449-456, 2008 | 3590 | 2008 |
| Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma RJ Motzer, NM Tannir, DF McDermott, O Arén Frontera, B Melichar, ... New England Journal of Medicine 378 (14), 1277-1290, 2018 | 3421 | 2018 |
| Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial B Escudier, A Pluzanska, P Koralewski, A Ravaud, S Bracarda, C Szczylik, ... The Lancet 370 (9605), 2103-2111, 2007 | 2833 | 2007 |
| Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors RJ Motzer, B Escudier, S Oudard, TE Hutson, C Porta, S Bracarda, ... Cancer 116 (18), 4256-4265, 2010 | 1446 | 2010 |
| Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma S Negrier, B Escudier, C Lasset, JY Douillard, J Savary, C Chevreau, ... New England Journal of Medicine 338 (18), 1272-1278, 1998 | 1188 | 1998 |
| Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 … T Powles, I Durán, MS Van der Heijden, Y Loriot, NJ Vogelzang, ... The Lancet 391 (10122), 748-757, 2018 | 1182 | 2018 |
| Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival B Escudier, J Bellmunt, S Négrier, E Bajetta, B Melichar, S Bracarda, ... J Clin Oncol 28 (13), 2144-50, 2010 | 1007 | 2010 |
| Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma DF McDermott, MA Huseni, MB Atkins, RJ Motzer, BI Rini, B Escudier, ... Nature medicine 24 (6), 749-757, 2018 | 867 | 2018 |
| Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial G Gravis, K Fizazi, F Joly, S Oudard, F Priou, B Esterni, I Latorzeff, ... The lancet oncology 14 (2), 149-158, 2013 | 792 | 2013 |
| Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma A Méjean, A Ravaud, S Thezenas, S Colas, JB Beauval, K Bensalah, ... New England Journal of Medicine 379 (5), 417-427, 2018 | 785 | 2018 |
| Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3 … BI Rini, T Powles, MB Atkins, B Escudier, DF McDermott, C Suarez, ... The Lancet 393 (10189), 2404-2415, 2019 | 767 | 2019 |
| Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy A Ravaud, RJ Motzer, HS Pandha, DJ George, AJ Pantuck, A Patel, ... New england journal of medicine 375 (23), 2246-2254, 2016 | 723 | 2016 |
| Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy L Capuron, A Ravaud, PJ Neveu, AH Miller, M Maes, R Dantzer Molecular psychiatry 7 (5), 468-473, 2002 | 606 | 2002 |
| Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised … RJ Motzer, BI Rini, DF McDermott, OA Frontera, HJ Hammers, ... The Lancet Oncology 20 (10), 1370-1385, 2019 | 585 | 2019 |
| Avelumab, an anti–programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase ib study AB Apolo, JR Infante, A Balmanoukian, MR Patel, D Wang, K Kelly, ... Journal of Clinical Oncology 35 (19), 2117, 2017 | 583 | 2017 |
| Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial MR Patel, J Ellerton, JR Infante, M Agrawal, M Gordon, R Aljumaily, ... The Lancet Oncology 19 (1), 51-64, 2018 | 535 | 2018 |
| Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma TK Choueiri, A Plantade, P Elson, S Negrier, A Ravaud, S Oudard, ... Journal of Clinical Oncology 26 (1), 127-131, 2008 | 489 | 2008 |
| Predictors of early death risk in older patients treated with first-line chemotherapy for cancer P Soubeyran, M Fonck, C Blanc-Bisson, JF Blanc, J Ceccaldi, C Mertens, ... Journal of Clinical Oncology 30 (15), 1829-1834, 2012 | 451 | 2012 |
| Prognostic factors of survival and rapid progression in782 patients with metastatic renal carcinomas treated by cytokines: A report from the Groupe Français d’Immunothérapie S Negrier, B Escudier, F Gomez, JY Douillard, A Ravaud, C Chevreau, ... Annals of Oncology 13 (9), 1460-1468, 2002 | 416 | 2002 |
